The DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Advances and Challenges of Liposome Assisted Drug Delivery
Open accessAbstract
The application of liposomes to assist drug delivery has already had a major impact on many biomedical areas. They have been shown to be beneficial for stabilizing therapeutic compounds, overcoming obstacles to cellular and tissue uptake, and improving biodistribution of compounds to target sites in vivo. This enables effective delivery of encapsulated compounds to target sites while minimizing systemic toxicity. Liposomes present as an attractive delivery system due to their flexible physicochemical and biophysical properties, which allow easy manipulation to address different delivery considerations. Despite considerable research in the last 50 years and the plethora of positive results in preclinical studies, the clinical translation of liposome assisted drug delivery platforms has progressed incrementally. In this review, we will discuss the advances in liposome assisted drug delivery, biological challenges that still remain, and current clinical and experimental use of liposomes for biomedical applications. The translational obstacles of liposomal technology will also be presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.
Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., Northrop, J. P., Ringold, G. M., & Danielsen, M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7413 · Cited by 4,978
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Drug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552
Nanoparticles in Medicine: Therapeutic Applications and Developments
Zhang, L., Gu, F., Chan, J., Wang, A., Langer, R., & Farokhzad, O. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100400 · Cited by 2,657
Toxicity of cationic lipids and cationic polymers in gene delivery
Lv, H., Zhang, S., Wang, B., Cui, S., & Yan, J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.04.014 · Cited by 2,286
Liposomes as nanomedical devices
Bozzuto, G., & Molinari, A. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s68861 · Cited by 2,261
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Openings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689
Gabizón, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., & Barenholz, Y. (1994) · PubMed · Cited by 1,382
Nanomedicine—Challenge and Perspectives
Riehemann, K., Schneider, S. W., Luger, T. A., Godin, B., Ferrari, M., & Fuchs, H. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802585 · Cited by 1,305
Moghimi, S. M., & Szebeni, J. (2003) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00033-x · Cited by 1,227
C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity
Dempsey, P. W., Allison, M. E. D., Akkaraju, S., Goodnow, C. C., & Fearon, D. T. (1996) · Science · doi:10.1126/science.271.5247.348 · Cited by 1,197
Kirpotin, D. B., Drummond, D. C., Shao, Y., Shalaby, M. R., Hong, K., Nielsen, U. B., Marks, J. D., Benz, C. C., & Park, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4199 · Cited by 1,125
Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic
Puri, A., Loomis, K., Smith, B., Lee, J.-H., Yavlovich, A., Heldman, E., & Blumenthal, R. (2009) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v26.i6.10 · Cited by 1,069
Yeh, M.-K., Chang, H.-I., & Cheng, M.-Y. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s26766 · Cited by 801
Needham, D., Anyarambhatla, G., Kong, G., & Dewhirst, M. W. (2000) · PubMed · Cited by 746
Current Trends in The Use of Liposomes for Tumor Targeting
Deshpande, P. P., Biswas, S., & Torchilin, V. P. (2013) · Nanomedicine · doi:10.2217/nnm.13.118 · Cited by 657
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park, J. W., Hong, K., Kirpotin, D. B., Colbern, G. T., Shalaby, R., Baselga, J. M., Shao, Y. Y., Nielsen, U. B., Marks, J. D., Moore, D. H., et al. (2002) · PubMed · Cited by 652
Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity
Szebeni, J. (2005) · Toxicology · doi:10.1016/j.tox.2005.07.023 · Cited by 611
Dams, E. T. M., Laverman, P., Oyen, W. J. G., Storm, G., Scherphof, G. L., van der Meer, J. W. M., Corstens, F. H. M., & Boerman, O. C. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35391-1 · Cited by 607
Kraft, J. C., Freeling, J. P., Wang, Z., & Ho, R. J. Y. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23773 · Cited by 606
Fate and behavior of liposomes in vivo: a review of controlling factors.
Senior, J. H. (1987) · PubMed · Cited by 591
Ishida, T., Ichihara, M., Wang, X., Yamamoto, K., Kimura, J., Majima, E., & Kiwada, H. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.01.005 · Cited by 557
Nanomedicines: addressing the scientific and regulatory gap
Tinkle, S., McNeil, S. E., Mühlebach, S., Bawa, R., Borchard, G., Barenholz, Y. (., Tamarkin, L., & Desai, N. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12403 · Cited by 546
Hua, S., Marks, E., Schneider, J. J., & Keely, S. (2015) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.02.018 · Cited by 494
Self-citationAccelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes
Ishida, T., & Kiwada, H. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.11.005 · Cited by 490
Biophysical Aspects of Using Liposomes as Delivery Vehicles
Ulrich, A. S. (2002) · Bioscience Reports · doi:10.1023/a:1020178304031 · Cited by 472
Increased exposure of anionic phospholipids on the surface of tumor blood vessels.
Ran, S., Downes, A., & Thorpe, P. E. (2002) · PubMed · Cited by 471
Chemical Approaches to Triggerable Lipid Vesicles for Drug and Gene Delivery
Guo, X., & Szoka, F. C. (2003) · Accounts of Chemical Research · doi:10.1021/ar9703241 · Cited by 456
Long-circulating (sterically stabilized) liposomes for targeted drug delivery
Allen, T. M. (1994) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(94)90314-x · Cited by 445
Kirpotin, D., Park, J. W., Hong, K., Zalipsky, S., Li, W.-L., Carter, P., Benz, C. C., & Papahadjopoulos, D. (1997) · Biochemistry · doi:10.1021/bi962148u · Cited by 439
Ligand-targeted liposomal anticancer drugs
Sapra, P., & Allen, T. M. (2003) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00032-8 · Cited by 438
Liposomes in tissue engineering and regenerative medicine
Monteiro, N., Martins, A., Reis, R. L., & Neves, N. M. (2014) · Journal of The Royal Society Interface · doi:10.1098/rsif.2014.0459 · Cited by 427
Intestinal barrier in inflammatory bowel disease
Antoni, L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i5.1165 · Cited by 413
Semple, S. C., Chonn, A., & Cullis, P. R. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00128-2 · Cited by 402
Lyass, O., Uziely, B., Ben-Yosef, R., Tzemach, D., Heshing, N. I., Lotem, M., Brufman, G., & Gabizon, A. (2000) · Cancer · doi:10.1002/1097-0142(20000901)89:5<1037::aid-cncr13>3.0.co;2-z · Cited by 385
Challenges in Development of Targeted Liposomal Therapeutics
Sawant, R. R., & Torchilin, V. P. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9330-0 · Cited by 379
Northfelt, D. W., Martin, F. J., Working, P., Volberding, P. A., Russell, J., Newman, M., Amantea, M. A., & Kaplan, L. D. (1996) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1996.tb04152.x · Cited by 378
Campbell, R. B., Fukumura, D., Brown, E. B., Mazzola, L. M., Izumi, Y., Jain, R. K., Torchilin, V. P., & Munn, L. L. (2002) · PubMed · Cited by 372
Ishida, T., Harada, M., Wang, X. Y., Ichihara, M., Irimura, K., & Kiwada, H. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.04.003 · Cited by 365
Zhang, J. A., Anyarambhatla, G., Ma, L., Ugwu, S., Xuan, T., Sardone, T., & Ahmad, I. (2005) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.06.009 · Cited by 334
Thermosensitive polymer-modified liposomes
Kono, K. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00204-6 · Cited by 303
In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
Gabizón, A., Horowitz, A. T., Goren, D., Tzemach, D., Shmeeda, H., & Zalipsky, S. (2003) · PubMed · Cited by 295
Forssen, E., & Willis, M. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00083-5 · Cited by 287
Holmén Larsson, J. M., Karlsson, H., Sjövall, H., & Hansson, G. C. (2009) · Glycobiology · doi:10.1093/glycob/cwp048 · Cited by 281
Hyperthermia mediated liposomal drug delivery
Ponce, A. M., Vujaskovic, Z., Yuan, F., Needham, D., & Dewhirst, M. W. (2006) · International Journal of Hyperthermia · doi:10.1080/02656730600582956 · Cited by 279
Ishida, T., Ichihara, M., Wang, X., & Kiwada, H. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.08.001 · Cited by 270
The use of lipid-based nanocarriers for targeted pain therapies
Hua, S., & Wu, S. Y. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00143 · Cited by 268
Self-citationAnthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.
Rahman, A. M., Yusuf, S. W., & Ewer, M. S. (2007) · PubMed Central · Cited by 267
Gabizón, A., Dagan, A., Goren, D., Barenholz, Y., & FUKS, Z. Y. (1982) · PubMed · Cited by 263
Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect
Greish, K., Nehoff, H., Parayath, N., Domanovitch, L., & Taurin, S. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s47129 · Cited by 238
Gabizon, A. A., Barenholz, Y., & Bialer, M. (1993) · Pharmaceutical Research · doi:10.1023/a:1018907715905 · Cited by 237
Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection
Clancy, J. P., Dupont, L., Konstan, M. W., Billings, J., Fustik, S., Goss, C. H., Lymp, J., Minic, P., Quittner, A. L., Rubenstein, R. C., et al. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-202230 · Cited by 222
Development and characterization of a novel liposome-based formulation of SN-38
Zhang, J. A., Xuan, T., Parmar, M., Ma, L., Ugwu, S., Ali, S., & Ahmad, I. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2003.10.015 · Cited by 220
Targeted accumulation of polyethylene glycol‐coated immunoliposomes in infarcted rabbit myocardium
Torchilin, V. P., Klibanov, A. L., Huang, L., O'Donnell, S., Nossiff, N. D., & Khaw, B. A. (1992) · The FASEB Journal · doi:10.1096/fasebj.6.9.1612296 · Cited by 216
Ishida, T., Kirchmeier, M. J., Moase, E. H., Zalipsky, S., & Allen, T. M. (2001) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(01)00409-6 · Cited by 216
Moein Moghimi, S., Hamad, I., Andresen, T. L., Jørgensen, K., Szebeni, J., Moein Moghimi, S., Hamad, I., Andresen, T. L., Jørgensen, K., & Szebeni, J. (2006) · The FASEB Journal · doi:10.1096/fj.06-6186fje · Cited by 201
Szebeni, J., Alving, C. R., Rosivall, L., Bünger, R., Baranyi, L., Bedöcs, P., Tóth, M., & Barenholz, Y. (2007) · Journal of Liposome Research · doi:10.1080/08982100701375118 · Cited by 199
Accelerated clearance of a second injection of PEGylated liposomes in mice
Ishida, T., Masuda, K., Ichikawa, T., Ichihara, M., Irimura, K., & Kiwada, H. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(03)00085-1 · Cited by 183
Advanced Drug Delivery Systems That Target The Vascular Endothelium
Ding, B.-S. (2006) · Molecular Interventions · doi:10.1124/mi.6.2.7 · Cited by 182
Nanotechnology and Nanomedicine: Going Small Means Aiming Big
Kumar Teli, M., Mutalik, S., & Rajanikant, G. K. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791208992 · Cited by 177
Szebeni, J., Fontana, J. L., Wassef, N. M., Mongan, P. D., Morse, D. S., Dobbins, D. E., Stahl, G. L., Bünger, R., & Alving, C. R. (1999) · Circulation · doi:10.1161/01.cir.99.17.2302 · Cited by 176
Inhaled Amikacin for Treatment of Refractory Pulmonary Nontuberculous Mycobacterial Disease
Olivier, K. N., Shaw, P. A., Glaser, T. S., Bhattacharyya, D., Fleshner, M., Brewer, C. C., Zalewski, C. K., Folio, L. R., Siegelman, J. R., Shallom, S., et al. (2014) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201307-231oc · Cited by 176
Webb, M. S., Saxon, D., Wong, F. M. P., Lim, H. J., Wang, Z., Bally, M. B., Choi, L. S. L., Cullis, P. R., & Mayer, L. D. (1998) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(98)00077-7 · Cited by 171
Transferrin as a Luminal Target for Negatively Charged Liposomes in the Inflamed Colonic Mucosa
Tirosh, B., Khatib, N., Barenholz, Y., Nissan, A., & Rubinstein, A. (2009) · Molecular Pharmaceutics · doi:10.1021/mp9000926 · Cited by 166
Drug delivery to inflamed colon by nanoparticles: Comparison of different strategies
Coco, R., Plapied, L., Pourcelle, V., Jérôme, C., Brayden, D. J., Schneider, Y.-J., & Préat, V. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.07.017 · Cited by 162
Andresen, T. L., Davidsen, J., Begtrup, M., Mouritsen, O. G., & Jørgensen, K. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm031029r · Cited by 158
Development of ligand-targeted liposomes for cancer therapy
Noble, C. O., Kirpotin, D. B., Hayes, M. E., Mamot, C., Hong, K., Park, J. W., Benz, C. C., Marks, J. D., & Drummond, D. C. (2004) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.8.4.335 · Cited by 157
Translational nanomedicine: status assessment and opportunities
Murday, J. S., Siegel, R. W., Stein, J. A., & Wright, J. F. (2009) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2009.06.001 · Cited by 155
Rip, J., Chen, L., Hartman, R., van den Heuvel, A., Reijerkerk, A., van Kregten, J., van der Boom, B. G., Appeldoorn, C. C. M., de Boer, M., Maussang, D., et al. (2014) · Journal of drug targeting · doi:10.3109/1061186x.2014.888070 · Cited by 154
Yarmolenko, P., Zhao, Y., Landon, C. D., Spasojević, I., Yuan, F., Needham, D., Viglianti, B. L., & Dewhirst, M. W. (2010) · International Journal of Hyperthermia · doi:10.3109/02656731003789284 · Cited by 154
Capture of Stealth Nanoparticles by the Body’s Defences
Moghimi, S. M., & Hunter, A. C. (2001) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v18.i6.30 · Cited by 154
Trigger release liposome systems: local and remote controlled delivery?
Bibi, S., Lattmann, E., Mohammed, A. R., & Perrie, Y. (2011) · Journal of Microencapsulation · doi:10.3109/02652048.2011.646330 · Cited by 151
Gabizón, A., Chisin, R., Amselem, S., Druckmann, S., Cohen, R., Goren, D., Fromer, I. R., Peretz, T., Sulkes, A., & Barenholz, Y. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.476 · Cited by 144
Awada, A. H., Bondarenko, I., Bonneterre, J. M., Nowara, E., Ferrero, J.-M., Bakshi, A. V., Wilke, C., & Piccart, M. J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu025 · Cited by 142
Kunstfeld, R., Wickenhauser, G., Michaelis, U., Teifel, M., Umek, W. H., Naujoks, K., Wolff, K. S., & Petzelbauer, P. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12057.x · Cited by 139
Liposomes in the treatment of inflammatory disorders
Metselaar, J. M., & Storm, G. (2005) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2.3.465 · Cited by 139
Peterson, C. G., Eklund, E., Taha, Y., Raab, Y., & Carlson, M. (2002) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05837.x · Cited by 137
Chapter 4 Lipid Vesicles as Carriers for Introducing Biologically Active Materials into Cells
Poste, G. H., Papahadjopoulos, D., & Vail, W. J. (1976) · Methods in cell biology · doi:10.1016/s0091-679x(08)60468-9 · Cited by 133
Oku, N., & Namba, Y. (1994) · PubMed · Cited by 129
Liposome triggering of innate immune responses: A perspective on benefits and adverse reactions
Szebeni, J., & Moghimi, S. M. (2009) · Journal of Liposome Research · doi:10.1080/08982100902792855 · Cited by 128
Dicheva, B. M., ten Hagen, T. L. M., Li, L., Schipper, D., Seynhaeve, A. L. B., van Rhoon, G. C., Eggermont, A. M. M., Lindner, L. H., & Koning, G. A. (2012) · Nano Letters · doi:10.1021/nl3014154 · Cited by 122
Narang, A., Chang, R.-K., & Hussain, M. A. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23691 · Cited by 122
Carlson, M., Raab, Y., Peterson, C. G. B., et al. (1999) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01223.x · Cited by 115
Hua, S. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00127 · Cited by 113
Self-citationMauro Ferrari, B. (2005) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2005.06.001 · Cited by 113
Multifunctional nanoparticles for use in theranostic applications
Cole, J. T., & Holland, N. B. (2015) · Drug Delivery and Translational Research · doi:10.1007/s13346-015-0218-2 · Cited by 109
Maruyama, K. (2002) · Bioscience Reports · doi:10.1023/a:1020138622686 · Cited by 109
Löhr, M. J., Haas, S., Bechstein, W. O., Bodoky, G., Cwiertka, K., Fischbach, W., Fölsch, U. R., Jäger, D., Osinsky, D., Prausová, J., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr379 · Cited by 108
Fighting Cancer: From the Bench to Bedside Using Second Generation Cationic Liposomal Therapeutics
Campbell, R. B., Ying, B., Kuesters, G. M., & Hemphill, R. L. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21458 · Cited by 107
Drug delivery systems for differential release in combination therapy
Zhang, H., Wang, G., & Yang, H. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.547470 · Cited by 105
Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
Chang, T. C., Shiah, H. S., Yang, C. H., Yeh, K. H., Cheng, A. L., Shen, B. N., Wang, Y. W., Yeh, C. G., Chiang, N. J., Chang, J. Y., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2671-x · Cited by 100
Interactions of Liposomes with Cells In Vitro and In Vivo: Opsonins and Receptors
Ishida, T., Harashima, H., & Kiwada, H. (2001) · Current Drug Metabolism · doi:10.2174/1389200013338306 · Cited by 94
Liposomes for scintigraphic detection of infection and inflammation
Laverman, P. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00095-7 · Cited by 93
Vascular targeting of doxorubicin using cationic liposomes
Wu, J. H., Lee, A., Lu, Y., & Lee, R. J. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.01.003 · Cited by 90
Immunoliposomes and PEGylated Immunoliposomes: Possible Use for Targeted Delivery of Imaging Agents
Torchilin, V. P. (1994) · ImmunoMethods · doi:10.1006/immu.1994.1027 · Cited by 89
Targeted drug delivery systems for the intracellular delivery of macromolecular drugs
Koning, G. A., & Storm, G. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02699-0 · Cited by 85
Seiden, M. V., Muggia, F. M., Astrow, A., Matulonis, U. A., Campos, S., Roche, M. R., Sivret, J., Rusk, J., & Barrett, E. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.12.037 · Cited by 84
Özpolat, B., Lopez‐Berestein, G., Adamson, P. C., Fu, C. J., & Williams, A. H. (2003) · PubMed · Cited by 81
Lipid-based carriers: manufacturing and applications for pulmonary route
Jaafar‐Maalej, C., Elaïssari, A., & Fessi, H. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.702751 · Cited by 78
Bendas, G. (2001) · BioDrugs · doi:10.2165/00063030-200115040-00002 · Cited by 74
Suenaga, M., Mizunuma, N., Matsusaka, S., Shinozaki, E., Ozaka, M., Ogura, M., & Yamaguchi, T. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s85567 · Cited by 70
Dicheva, B. M., ten Hagen, T. L. M., Schipper, D., Seynhaeve, A. L. B., van Rhoon, G. C., Eggermont, A. M. M., & Koning, G. A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.07.058 · Cited by 66
Are PEGylated liposomes better than conventional liposomes? A special case for vincristine
Wang, X., Song, Y., Su, Y., Tian, Q., Li, B., Quan, J., & Deng, Y. (2015) · Drug Delivery · doi:10.3109/10717544.2015.1027015 · Cited by 64
Storm, G., ten Kate, M. T., Working, P. K., & Bakker‐Woudenberg, I. A. J. M. (1998) · PubMed · Cited by 64
Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma.
Ning, Y. M., He, K., Dagher, R. N., et al. (2007) · PubMed · Cited by 64
Zamboni, W. C., Ramalingam, S. S., Friedland, D., Edwards, R. P., Stoller, R. G., Strychor, S., Maruca, L. J., Zamboni, B. A., Belani, C. P., & Ramanathan, R. K. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1405 · Cited by 63
Hua, S. (2013) · Pain Physician · doi:10.36076/ppj.2013/16/e199 · Cited by 63
Self-citationDark, G. G., Calvert, H., Grimshaw, R. N., Poole, C. J., Swenerton, K., Kaye, S. B., Coleman, R. E., Jayson, G. C., Le, T. V., Ellard, S. L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.028 · Cited by 58
Offner, F. C., Krcmery, V., Boogaerts, M., Doyen, C., Engelhard, D., Ribaud, P., Cordonnier, C., de Pauw, B., Durrant, S., Marie, J., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4808-4812.2004 · Cited by 58
Hua, S., & Cabot, P. J. (2013) · PubMed · Cited by 51
Self-citationLiposomal siRNA for Ovarian Cancer
Mangala, L. S., Han, H. D., Lopez‐Berestein, G., & Sood, A. K. (2009) · Methods in molecular biology · doi:10.1007/978-1-60327-295-7_3 · Cited by 48
Self-citationWetzler, M., Thomas, D. A., Wang, E. S., Shepard, R. C., Ford, L. A., Heffner, T. L., Parekh, S. S., Andreeff, M., O'Brien, S. M., & Kantarjian, H. M. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.03.015 · Cited by 45
Gross, N. J., Ranjbar, M., Evers, C., Hua, J., Martin, G., Schulze, B. G., Michaelis, U., Hansen, L. L., & Agostini, H. T. (2013) · Europe PMC (PubMed Central) · Cited by 45
Theranostic Lipid Nanoparticles for Cancer Medicine
Charron, D. M., Chen, J., & Zheng, G. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-16555-4_5 · Cited by 40
Laverman, P., Carstens, M. G., Storm, G., & Moghimi, S. M. (2001) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(01)00142-8 · Cited by 33
Klimuk, S. K., Semple, S. C., Scherrer, P., & Hope, M. J. (1999) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(98)00261-2 · Cited by 29
Giannella, M., Ercolani, G., Cristini, F., Morelli, M. C., Bartoletti, M., Bertuzzo, V. R., Tedeschi, S., Faenza, S., Puggioli, C., Lewis, R. E., et al. (2014) · Transplantation · doi:10.1097/tp.0000000000000393 · Cited by 26
Safety and Efficacy of Liposomal Cytarabine in the Treatment of Neoplastic Meningitis
Jahn, F., Jordan, K., Behlendorf, T., Globig, C., Schmoll, H., Müller‐Tidow, C., & Jordan, B. (2015) · Oncology · doi:10.1159/000380913 · Cited by 18
Chandrasekar, P. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s1554 · Cited by 11
Cited by
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Nano based drug delivery systems: recent developments and future prospects
Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S., et al. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0392-8 · Cited by 6,684
Controlled Drug Delivery Systems: Current Status and Future Directions
Adepu, S., & Ramakrishna, S. (2021) · Molecules · doi:10.3390/molecules26195905 · Cited by 1,691
Liposomes: Structure, composition, types, and clinical applications
Nsairat, H., Khater, D., Sayed, U., Odeh, F., Al Bawab, A., & Alshaer, W. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09394 · Cited by 1,561
Ha, D., Yang, N., & Nadithe, V. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.02.001 · Cited by 1,346
Metadata
- Authors
- Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2015-12-01
- Volume
- 6
- Pages
- 286-286
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2187976253
- Cited by
- 2,632
- References
- 120
- FWCI
- 31.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.